Martha Rook - Delcath Systems Chief Officer
| DCTH Stock | USD 9.31 0.19 2.08% |
Executive
Martha Rook is Chief Officer of Delcath Systems
| Age | 55 |
| Address | 566 Queensbury Avenue, New York, NY, United States, 12804 |
| Phone | 212 489 2100 |
| Web | https://www.delcath.com |
Delcath Systems Management Efficiency
The company has return on total asset (ROA) of 0.0472 % which means that it generated a profit of $0.0472 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0194 %, meaning that it created $0.0194 on every $100 dollars invested by stockholders. Delcath Systems' management efficiency ratios could be used to measure how well Delcath Systems manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.42. The current Return On Capital Employed is estimated to decrease to -0.21. As of now, Delcath Systems' Fixed Asset Turnover is increasing as compared to previous years. The Delcath Systems' current Asset Turnover is estimated to increase to 0.46, while Non Currrent Assets Other are projected to decrease to (0.94).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brent Moen | Tactile Systems Technology | 57 | |
| Scott Schaper | Neuropace | N/A | |
| Ido Marom | Brainsway | 50 | |
| Chris Reese | Neuropace | N/A | |
| John Dalton | Kindly MD | 44 | |
| Chrystal Jensen | Cerus | 53 | |
| Katie Keller | Neuropace | N/A | |
| Kenny Bellendir | agilon health | N/A | |
| Tyler Evans | Kindly MD | 34 | |
| Martha MD | Neuropace | 69 | |
| Matthew CFA | agilon health | N/A | |
| Jim Schindler | Rxsight | N/A | |
| JD Esq | 908 Devices | 58 | |
| Rachel Gustad | Tactile Systems Technology | N/A | |
| Irina Ridley | Neuropace | 38 | |
| Hillegonda Groen | Brainsway | 56 | |
| Richard MD | Brainsway | N/A | |
| Peter Schaubach | Tactile Systems Technology | N/A | |
| Hadar Levy | Brainsway | 52 | |
| Kyle Simon | Kindly MD | N/A | |
| Kenneth JD | Senseonics Holdings Common | 59 | |
Management Performance
| Return On Equity | 0.0194 | ||||
| Return On Asset | 0.0472 |
Delcath Systems Leadership Team
Elected by the shareholders, the Delcath Systems' board of directors comprises two types of representatives: Delcath Systems inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Delcath. The board's role is to monitor Delcath Systems' management team and ensure that shareholders' interests are well served. Delcath Systems' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Delcath Systems' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robin Wagge, VP Associates | ||
| David Hoffman, Corporate Counsel | ||
| MD MSc, Chief Officer | ||
| Kevin Muir, VP Operations | ||
| Johnny MD, Senior Affairs | ||
| Sandra Pennell, Senior Officer | ||
| Vojislav MD, Chief Officer | ||
| MS MBA, CEO Director | ||
| John MS, Chief Officer | ||
| Sandra CPA, Senior Officer | ||
| David JD, Corporate Counsel | ||
| Michael MD, Senior Oncology | ||
| Martha Rook, Chief Officer | ||
| Anthony Dias, VP Fin |
Delcath Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Delcath Systems a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0194 | ||||
| Return On Asset | 0.0472 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 235.28 M | ||||
| Shares Outstanding | 34.7 M | ||||
| Shares Owned By Insiders | 2.85 % | ||||
| Shares Owned By Institutions | 50.45 % | ||||
| Number Of Shares Shorted | 4.21 M | ||||
| Price To Earning | (0.12) X |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Delcath Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more detail on how to invest in Delcath Stock please use our How to Invest in Delcath Systems guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is there potential for Health Care Equipment & Supplies market expansion? Will Delcath introduce new products? Factors like these will boost the valuation of Delcath Systems. Projected growth potential of Delcath fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Delcath Systems listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.67) | Earnings Share 0.03 | Revenue Per Share | Quarterly Revenue Growth 0.836 | Return On Assets |
The market value of Delcath Systems is measured differently than its book value, which is the value of Delcath that is recorded on the company's balance sheet. Investors also form their own opinion of Delcath Systems' value that differs from its market value or its book value, called intrinsic value, which is Delcath Systems' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Delcath Systems' market value can be influenced by many factors that don't directly affect Delcath Systems' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Delcath Systems' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Delcath Systems should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Delcath Systems' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.